Opens in a new tab

Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023)

Date20 November 2023
CourtCFI
DivisionMunich (DE) Central Division - Section
Type of actionRevocation Action
Case number(s)UPC_CFI_80/2023
Registry referenceORD_579547/2023 · UPC_CFI_80/2023
PartiesASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE v. HELIOS K.K, OSAKA UNIVERSITY

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 20 November 2023 (UPC_CFI_80/2023, ACT_465342/2023, App_577540/2023), panel 1 of the Munich Central Division (U. Voß, presiding, A. Kupecz, judge-rapporteur, P. Gerli, technically qualified judge) rejected the request of Healios K.K and Osaka University, proprietors of EP 3 056 564, to stay the revocation action brought by Astellas Institute for Regenerative Medicine pending the EPO opposition, in which the Opposition Division hearing is set for 4 March 2024. Leave to appeal was granted.

Question

Does an Opposition Division decision expected shortly, but open to appeal, justify a stay under Art. 33(10) UPCA and Rule 295(a) RoP?

Decision

The « rapid » decision referred to in Art. 33(10) UPCA need not be the final EPO decision: any relevant decision expected rapidly may suffice, provided a concrete and near date is established. The panel doubts that a decision expected in just over three months is rapid, but assumes that it is. An appeal is highly likely, the defendants having given no undertaking not to appeal, and a final decision is expected around mid-2028. The claimant’s interest in early legal certainty outweighs the saving in costs. The risk of conflicting decisions does not make a stay proportionate at this stage. The action continues at least until the interim conference of 14 March 2024, the panel stating that it is minded to postpone the hearing or stay if the patent is revoked.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 33(8) and (10) and Art. 73(2)(b)(ii)
Rules of Procedure
Preamble points 2, 4, 5 and 8, Rules 220.2, 224.1(b), 295(a) and 296.3
European Patent Convention
Art. 106(1)
Case law cited
Edwards Lifesciences v Meril Italy, Paris Central Division, 13 November 2023

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Revocation action.

Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_80/2023 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 11 October 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_80/2023, 11 October 2023) Revocation Action · UPC_CFI_80/2023

    Le mémoire en défense à l'action en nullité est réputé signifié à la demanderesse le 29 septembre 2023, le délai de réponse à la demande de sursis sera fixé par une ordonnance distincte.

  2. 17 November 2023 Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 November 2023) Revocation Action · UPC_CFI_80/2023

    L'annexe confidentielle n'est accessible qu'aux représentants des défenderesses et à trois personnes physiques désignées, dont un conseil externe. Elle est soustraite à l'accès des tiers et l'appel est autorisé.

  3. 20 November 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023) Revocation Action · UPC_CFI_80/2023
  4. 18 March 2024 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024) Revocation Action · UPC_CFI_80/2023

    Le document D21 est admis sous réserve d'une réponse de la défenderesse avant le 11 avril 2024, la valeur du litige est fixée à 4 000 000 euros et l'audience confirmée au 26 juin 2024.

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
Le sursis à statuer sur l'action en nullité est refusé : une décision de la division d'opposition proche mais susceptible de recours n'emporte pas, à ce stade, une décision rapide justifiant la suspension, l'appel est autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.